Tradegate
15.07.25 | 21:10
5,550 Euro
+0,91 % +0,050
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,450 | 5,550 | 12:04 | |
| 5,400 | 5,550 | 10:39 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.06. | Silence Therapeutics plc - 8-K, Current Report | 3 | SEC Filings | ||
| 13.06. | H.C. Wainwright reiterates buy rating on Silence Therapeutics stock | 2 | Investing.com | ||
| 12.06. | Silence Therapeutics plc: Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera | 398 | Business Wire | Updated Phase 1 Data Presented at EHA 2025 Annual Meeting Reinforce Safety Profile, Efficacy Data and Dosing Convenience of Divesiran Company Also Announces SANRECO Phase 2 Study Has Exceeded... ► Artikel lesen | |
| 08.05. | Silence Therapeutics plc GAAP EPS of -C$0.20 | 4 | Seeking Alpha | ||
| 08.05. | Silence Therapeutics plc - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 08.05. | Silence Therapeutics plc: Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights | 1.044 | Business Wire | Company further extends cash guidance into 2028
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA)... ► Artikel lesen | |
| 06.05. | Silence Therapeutics plc - 8-K, Current Report | 3 | SEC Filings | ||
| 06.05. | Silence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of Directors | 386 | Business Wire | Mr. McInerney brings over 30 years of industry experience spanning senior executive, finance and capital advisory roles in the pharmaceutical and biotechnology sectors
Silence Therapeutics plc... ► Artikel lesen | |
| SILENCE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 30.04. | Silence Therapeutics plc - 10-K/A, Annual Report | 2 | SEC Filings | ||
| 24.04. | Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying | 3 | Insider Monkey | ||
| 07.03. | H.C. Wainwright maintains $75 target on Silence Therapeutics stock | 3 | Investing.com | ||
| 05.03. | Silence Therapeutics plc: Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference | 321 | Business Wire | Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will present... ► Artikel lesen | |
| 05.03. | Morgan Stanley cuts Silence Therapeutics stock target to $45 | 4 | Investing.com | ||
| 04.03. | Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings) | 2 | Benzinga.com | ||
| 27.02. | Jefferies cuts Silence Therapeutics price target to $30 | 5 | Investing.com | ||
| 27.02. | Silence Therapeutics plc - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 27.02. | Silence Therapeutics plc - 10-K, Annual Report | - | SEC Filings | ||
| 27.02. | Silence Therapeutics plc - 8-K, Current Report | - | SEC Filings | ||
| 27.02. | Silence Therapeutics plc: Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update | 427 | Business Wire | The Company's cash guidance is now extended into 2027 Company to host conference call and webcast today at 8 a.m. EST 1 p.m. GMT
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company")... ► Artikel lesen | |
| 13.02. | Silence Therapeutics plc: Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025 | 375 | Business Wire | Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that the Company will... ► Artikel lesen |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 57,53 | -0,47 % | Novo investiert in China: Was jetzt zählt | Die Novo-Nordisk-Aktie notiert aktuell bei 61,15?EUR - nach einem gewaltigen Anstieg seit Jahresbeginn kommt es nun vermehrt zu Gegenwind. Zwischen regulatorischen Erfolgen, Partner-Enttäuschungen und... ► Artikel lesen | |
| GILEAD SCIENCES | 94,51 | +0,12 % | Gilead Sciences-Aktie verliert 4,36 Prozent (93,65 €) | Am US-amerikanischen Aktienmarkt liegt das Wertpapier von Gilead Sciences zur Stunde im Minus. Das Papier kostete zuletzt 93,65 Euro. Die Aktie von Gilead Sciences verzeichnet derzeit einen Abschlag... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 405,70 | +1,60 % | Vertex Pharmaceuticals Incorporated: Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis | All eligible people with CF in England can now benefit from this medicine - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has reached a broad reimbursement agreement... ► Artikel lesen | |
| INNOCAN PHARMA | 0,128 | -1,16 % | Neue Studie: Gamechanger für Innocan Pharma?! | ||
| IONIS PHARMACEUTICALS | 36,660 | -0,27 % | Ionis Pharmaceuticals: Spannender Ausblick | Das US-Biotechunternehmen Ionis Pharmaceuticals durchläuft derzeit eine hochspannende Phase. Ionis gilt als Pionier auf dem Gebiet der Antisense-Oligonukleotid-(ASO)-Technologie. In der Fachzeitschrift... ► Artikel lesen | |
| SNDL | 1,280 | +0,23 % | SNDL to Announce Second Quarter 2025 Financial Results on July 31, 2025 | ||
| ASSEMBLY BIOSCIENCES | 16,200 | 0,00 % | Assembly Biosciences: ABI-4334 erreicht Studienziel - Gilead-Entscheidung steht bevor | Assembly Biosciences (WKN: A402CB) liefert weiter ab: Mit ABI-4334 fällt der erste wichtige Readout dieses Jahres positiv aus. Das HBV-Asset galt als das unsicherste im Portfolio. Die Aktie liebäugelt... ► Artikel lesen | |
| HAPPY BELLY FOOD GROUP | 0,635 | -2,31 % | Happy Belly Food Group Inc.: Happy Belly Food Group's Rosie's Burgers Announces the Signing of a Franchise Agreement and Real Estate Location in Calgary's Marda Loop District, Alberta | Toronto, Ontario--(Newsfile Corp. - July 11, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging food brands is pleased... ► Artikel lesen | |
| ALNYLAM PHARMACEUTICALS | 275,80 | +4,15 % | A Glimpse Into The Expert Outlook On Alnylam Pharmaceuticals Through 10 Analysts | ||
| LIGAND PHARMACEUTICALS | 106,00 | -5,36 % | Ligand Pharma Earns Milestone Payment From Pelthos On Commercial Launch Of ZELSUVMI | WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals (LGND) announced that its partner Pelthos Therapeutics Inc. (PTHS) has commercially launched ZELSUVMI or berdazimer topical gel 10.3%, the first... ► Artikel lesen | |
| DARE BIOSCIENCE | 2,620 | 0,00 % | Daré Bioscience, Inc.: Positive Interim Phase 3 Results Highlight Potential of Ovaprene, Novel Hormone-Free Contraceptive | SAN DIEGO, July 14, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today... ► Artikel lesen | |
| HYTN INNOVATIONS | 0,108 | 0,00 % | HYTN sichert sich Cannabis-Arzneimittellizenz und erzielt Fortschritte im Zulassungsverfahren für verschreibungspflichtige Arzneimittel für Medikamente auf Cannabinoidbasis | Vancouver, British Columbia - 14. Juli 2025 / IRW-Press / HYTN Innovations Inc. (CSE: HYTN, FWB: 85W0, OTC PINK: HYTNF) ("HYTN" oder das "Unternehmen"), ein
führendes Unternehmen in der Herstellung... ► Artikel lesen | |
| MEI PHARMA | 3,860 | 0,00 % | MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position | SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the "Company") today reported results for its quarter ended December 31, 2024.
As previously announced in July 2024, the Company is... ► Artikel lesen | |
| WAVE LIFE SCIENCES | 6,500 | -3,70 % | Breaking Down WAVE Life Sciences: 4 Analysts Share Their Views | ||
| AKARI THERAPEUTICS | 0,970 | +3,19 % | Akari Therapeutics Plc: Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India | Differentiated PH1 payload is a spliceosome inhibitor designed to inhibit RNA splicing, leading to cancer cell death and activation of immune system through multiple mechanisms India represents a... ► Artikel lesen |
SILENCE THERAPEUTICS PLC ADR gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 5,550 Euro und damit +0,91 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILENCE THERAPEUTICS PLC ADR finden Sie auf Wallstreet Online.